Meet Our Cancer & Blood Disorders Institute Leadership

Dr. Clay is the division chief of hematology and director of the sickle cell program in the Johns Hopkins All Children's Cancer & Blood Disorders Institute. She is an assistant professor of pediatrics in the Johns Hopkins University School of Medicine. Dr. Clay treats children, adolescents and young adults with rare blood disorders such as sickle cell disease and thalassemia. Trained in both pediatrics and internal medicine, she plays the key role of a physician navigator in transitioning adolescents with these diseases to adult care. She has established her research in sickle cell disease where she studies the mechanistic contribution of vitamin D deficiency and its effects of disease manifestation of sickle cell disease as well as bone disease. Her primary professional objective is to translate her clinical research to the field.

Dr. Oshrine is the division chief of bone marrow transplant, and specializes in blood and marrow transplants as a pediatric hematologist/oncologist in the Johns Hopkins All Children’s Cancer & Bone Marrow Disorders Institute. His clinical focus is in the treatment of high-risk leukemias with blood and marrow transplantation, and his research focus is in immune recovery after transplant. He joined the hospital in 2014 after completing a fellowship in pediatric hematology/oncology at the Children’s Hospital of Philadelphia. Dr. Oshrine earned his medical degree from the University of Virginia School of Medicine and completed his residency at Boston Children’s Hospital.

Dr. Stapleton is the division chief of oncology and director of pediatric neuro-oncology at Johns Hopkins All Children’s Hospital. Dr. Stapleton joined the hospital in 2007 and is double-board certified by the American Board of Pediatrics in general pediatrics and pediatric hematology/oncology. She has formal training in pediatric neuro-oncology. Dr. Stapleton is on the Pediatric Palliative Care Team at Johns Hopkins All Children’s and she specializes in symptom control and end of life care. She has been awarded numerous grants for phase I studies for patients with brain and spinal cord tumors as well as clinical research in pediatric palliative care. Dr. Stapleton’s research experience includes investigator-initiated and multi-center research projects.

Dr. Shaw is hematologist-oncologist who serves as medical director of Tampa Services for the Johns Hopkins All Children’s Cancer & Blood Disorders Institute. He joined the medical staff in August 2016 as deputy director. Dr. Shaw treats a variety of patients with blood and cancer disorders at the Tampa clinic and is recognized nationally as a leader in the areas of adolescent and young adult (AYA) oncology. He is founding member of the Consortium of Adolescent and Young Adult Cancer Centers and helped develop internationally recognized standards for care of this population. He is expanding the AYA program at Johns Hopkins All Children’s to enhance continuity of care into adulthood through multidisciplinary collaboration with physicians at Moffitt Cancer Center. He also supports the institute’s fertility preservation program, which helps pediatric cancer and bone marrow transplant survivors enjoy optimal health and the opportunity to become parents in their adult years.

Michelle DuJardin leads the administration of the Johns Hopkins All Children’s Cancer and Blood Disorders Institute, and the Institute for Brain Protection Sciences. She joined the team in 2016 and has more than 18 years of health care and administrative experience. DuJardin is a certified Fellow of the American College of Medical Practice Executives. She earned her Bachelor of Science in Health Services Administration from the University of Central Arkansas and earned a law degree from the University of Arkansas at Little Rock. She spent much of her health care career at the University of Arkansas for Medical Sciences where she held various leadership and administrative roles in pediatric anesthesiology and neuroscience.